Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 12/20 | 0.39 |
| ▸ | KDR | P35968 | 12/20 | 0.39 |
| ▸ | KIT | P10721 | 7/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | TLK2 | Q86UE8 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 3/20 | 0.35 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.35 |
| ▸ | FLT1 | P17948 | 1/20 | 0.35 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6101501 | 1.00 | PDGFRB (0.39) | PDGFRBKDRKITGAAFGFR1 | |
| SCHEMBL4308604 | 0.90 | PDGFRB (0.43) | PDGFRBKDRKITFLT3 | |
| SCHEMBL6102326 | 0.90 | PDGFRB (0.40) | PDGFRBKDRKITFGFR1TLK2 | |
| SCHEMBL4308606 | 0.90 | PDGFRB (0.43) | PDGFRBKDRKITFLT3 | |
| SCHEMBL6102322 | 0.90 | PDGFRB (0.40) | PDGFRBKDRKITFGFR1TLK2 | |
| SCHEMBL6103573 | 0.86 | PDGFRB (0.41) | PDGFRBKDRKITFGFR1FLT3 | |
| SCHEMBL6103566 | 0.86 | PDGFRB (0.41) | PDGFRBKDRKITFGFR1FLT3 | |
| SCHEMBL6104928 | 0.86 | PDGFRB (0.39) | PDGFRBKDRKITGAAFGFR1 | |
| SCHEMBL6104933 | 0.86 | PDGFRB (0.39) | PDGFRBKDRKITGAAFGFR1 | |
| SCHEMBL4309393 | 0.85 | PDGFRB (0.38) | PDGFRBKDRKITFGFR1TLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004084-A1 | (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004084-A1 | (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | CDK2, ERBB2, MAP3K3 | PDGFRB 502/4885KDR 320/4885KIT 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.